tbuckley/cabot-search huggingface dataset:
FRI-464-Percutaneous microwave is better than radiofrequency ablation to obtain complete response in cirrhotic patients with very early and early hepatocellular carcinoma
Authors: Michela Ciruolo, Elena Mosso, Patrizia Carucci, Emanuela Rolle, Simone Vola, Alessandra Risso, Enrica Migliore, Giorgio Maria Saracco, Silvia Gaia
Journal: Journal of Hepatology (2019)
THU-084-A comparative study of anti-Fibrotic therapeutics using aptamer-based quantitative proteomics in a rat model of non-alcoholic steatohepatitis cirrhosis
Authors: Smitha Krishnan, Sarani Goshal, Simon Dillon, Ricard Masia, Diego Ferreira, Peter Caravan, Yang Li, Guoqiang Wang, Yat Sun Or, Lijuan Jiang, Kenneth K. Tanabe, Towia Libermann, Bryan C. Fuchs
Journal: Journal of Hepatology (2019)
Abstract 19275: Association Between Exposure to Different Beta-Blocker Subtypes During Pregnancy and the Risk of Low Birth Weight
Authors: Jennifer Nguyen, Angie Ng, Lewei Duan, Albert Yuh-Jer Shen, Mingsum Lee
Journal: Circulation (2016)

Introduction: Beta-blockers are one of the most commonly prescribed classes of cardiovascular medications during pregnancy. Previous studies reported an association between beta-blocker treatment a...
Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire
Authors: D. Sharma, F. Slevin, K. Clarke, K. Franks, M. Snee, P. Jain
Journal: Annals of Oncology (2019)

Background: In the UK approximately 10% of all patients diagnosed with NSCLC harbour an Epidermal Growth Factor Receptor (EGFR) mutation. Tyrosine kinase inhibitors (TKI) have been used as first-line treatment for this group of patients since 2009. We performed a retrospective analysis of our regional cohort to assess patient outcomes and document changes in practice over the years. Methods: Electronic paperless notes system (PPM) was used to collect data on 210 patients diagnosed with EGFR mutation positive NSCLC within West Yorkshire from 2009-2018. Information regarding patient characteristics, stage of cancer, treatment, toxicity and outcome was obtained. Descriptive statistics were performed and Graphpad Prism® was used to determine overall survival. Subgroup analyses were performed for exon mutation, performance status, TKI received and year treated. Results: Of 150 evaluable patients, 114 received first-line TKI, 3 received second-line TKI and 33 received no TKI. Median age was 72 (interquartile range 62-77). 10, 43 and 61 patients had exon 18, 19 and 21 mutations respectively. 93 patients treated with TKI were performance status (PS) 0-2 and 21 PS 3. 49 patients were treated 2009-13 and 65 2014-2018. Of the 33 patients who did not receive a TKI, 14 had no residual disease following another radical treatment modality, 14 were inappropriate for systemic treatment based on PS or EGFR resistance mutation and 2 declined any treatment. Median overall survival for the full cohort was 15.6 months. Statistically non-significant trends towards improved overall survival were seen in patients with PS ≤ 2 versus (vs.) PS 3 (17.8 vs. 9.9 months); exon 19 vs. 21 (19.1 vs. 14.3 months); treatment with Afatinib vs. Gefitinib or Erlotinib (21.3 vs. 12.8 and 13.8 months) and patients treated 2014-2018 vs. 2009-2013 (18.4 vs. 9.9 months). Compared to 2009-2013, in patients treated 2014-2018 Gefitinib use decreased (40 vs. 23) whilst Erlotinib (9 vs. 18) and Afatinib (0 vs. 24) use both increased. Conclusions: Our real-world data supports the published literature by demonstrating improved outcomes with TKI treatment in patients with exon 19 mutations, better PS and treatment more recently with second generation TKIs. Legal entity responsible for the study: The Leeds Teaching Hospitals NHS Trust. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Ribavirin And Interferon For Critically Ill Patients With Middle East Respiratory Coronavirus (mers-Cov) Infection
Authors: Y M Arabi, H Balkhy, A Al-Omari, F Al-Hameed, A Al-Aithan, A Abdulmomen, K Alkhatib, M Al-Ahmadi, J Whitehead, H Tamim, L Merson, F G Hayden, N Shindo, R Fowler
Journal: American Journal of Respiratory and Critical Care Medicine (2015)
Relationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion
Authors: J. Zhang, Z.S. Zhou, Y.C. Su, T.Q. Yu
Journal: Annals of Oncology (2019)

Background: To investigate the relationship of the clinical characteristics, EGFR genotyping and prognostic factors of malignant pleural effusion associated with non-small cell lung cancer (NSCLC). Methods: A total of 321 patients hospitalized in Guangxi Medical University Affiliated Tumor Hospital from November 2013 to December 2017 who were pathologically or cytologically confirmed NSCLC with malignant pleural effusion (MPE) were enrolled in the study. The information including clinical features at baseline, pleural effusion status, EGFR genomic alternation, treatment and prognosis for patients were retrospectively extracted and analyzed. The data were analyzed by SPSS 21.0 software. Chi-square test was used for comparison between groups, and Fisher's exact probability method was used for correction. Survival curves were drawn by Kaplan-Meier method, and the differences between groups were compared by log-rank test. P < 0.05 was considered as statistical significance. Results: There were significant differences in M staging, ECOG score and bone metastasis between patients with malignant pleural effusion at initial diagnosis and those with malignant pleural effusion at diseases progression (P < 0.05). The median overall survival for EGFR exon 19 deletion mutation, exon 21 L858R mutation and wild type in MPE patients were 21.8 months, 19.5 months and 11.6 months respectively (P = 0.005). The median overall survival for patients with EGFR sensitizing mutations treated with first- and second- generation EGFR-TKIs and those without TKI treatment was 21.9 months and 12.9 months respectively (P = 0.001). The median overall survival for wild type EGFR patients with simultaneous liver metastasis and non-liver metastasis was 5.8 months and 12.2 months respectively (P = 0.031). Conclusions: Through comparing clinicopathological characteristics, EGFR genotyping and prognosis in MPE patients, those whose MPE were identified at the time of diagnosis are more frequently a higher incidence of ECOG score and bone metastasis, a longer OS in patients with EGFR mutation and treated with EGFR-TKI, and a significantly lower OS in patients with wild-type EGFR and liver metastasis. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
THU-484-Mass spectrometric analysis of serum haptoglobin fucolysation in patients stratified according to fibrosis stages, and the presence of hepatocellular carcinoma
Authors: Valentina Peta, Prof. David Lubman, Dr Jianhui Zhu, Rezai Keyvan, Huguet Samuel, Imbert-Bismut Francoise, Bolbach Gerard, Codic Gilles, Matheron Lucrece, Chantal Housset, Thierry Poynard
Journal: Journal of Hepatology (2019)
THU-485-Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma
Authors: David James Pinato, Robert D. Goldin, Takashi Mineo, Abdul Siddique, Ayse Akarca, Teresa Marafioti, Claudio Avellini, Pierluigi Toniutto, Francesco Mauri, rohini sharma
Journal: Journal of Hepatology (2019)
THU-409-Progress on scaling up testing and treatment for hepatitis C elimination in Punjab, Pakistan: Hepatitis prevention and treatment program
Authors: Ammara Naveed, Amjad Khan, Asif Butt, Shabbar Ali, Farooq A. Khan, Khurram Anis, Arif Mahmood Siddique, Kamran Shafiq, Ahmad Karim Malik, Nauman Zakir, Amer Yar Khan, Saeed Akhter, Naveed Janjua, Abdul Nadir, Faisel Yunus
Journal: Journal of Hepatology (2019)
FRI-083-Impact of acetaminophen on acute liver failure of unknown cause
Authors: Claire Decoster, Celine Piedvache, Cèline Verstuyft, Helene Agostini, Anne Marie Roque-Afonso, Mylène Sebagh, Sebastien Dharancy, Christine Silvain, Vincent Di Martino, Armand Abergel, Christophe Duvoux, Vincent Leroy, Georges-Philippe Pageaux, Cyrille Feray, Rodolphe Anty, Helene Fontaine, Marika Rudler, Pauline Houssel-Debry, Nicolas Carbonell, Odile Goria, Camille Besch, Brigitte Bernard Chabert, Marilyne Debette-Gratien, Potier Pascal, Philippe Ichai, Didier Samuel, Audrey Coilly
Journal: Journal of Hepatology (2019)
Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center
Authors: I. Tsiouprou, V. Tsartsianidou, S. Papaemmanouil, N. Pastelli, S. Lampaki, E. Eleftheriadou, K. Domvri, T. Kontakiotis, D. Spyratos
Journal: Annals of Oncology (2019)

Background: Nowadays, cancer immunotherapy is rapidly evolving and monoclonal antibodies targeting the programmed death-1 receptor (PD-1) / PD ligand 1 (PD-L1) pathway have been approved for the treatment of NSCLC; however, there is lack of evidence regarding the current use of PD-L1 analysis in the everyday clinical practice. Methods: For this purpose we conducted a retrospective observational study in our lung cancer oncology unit. Eligible patients were adults of both sexes with non-small cell lung cancer who were treated in our department from April 2017 through December 2018. In total 123 patients were investigated regarding PD-L1 expression using the immunohistochemistry assay 22C3. Results: 108 out of 123 patients were male (87.8%) with a mean age of 67.5±9.3 years. Regarding smoking status there were 95 current smokers (77.2%), 27 former or never smokers (22%) and the mean pack-years were 45.9 ±36.78. Concerning lung cancer histology, 52 patients (42.3%) were diagnosed with squamous cell carcinoma, 63 (51.2%) with adenocarcinoma and 8 with NOS, adenosquamous and large cell carcinoma. At the time of initial diagnosis 59 of them (48%) were staged as IVA, 40 (32.5%) as stage I,II,III and 24 (19.5%) as IVB. Furthermore 11.4% had undergone surgical treatment and 13.8% of them radiotherapy. Out of the 123 specimens, 4 were non eligible for PD-L1 IHC analysis (<100 malignant cells/optical field). Sixty seven patients (54.5%) had PD-L1 TPS scores <1% and 20 (16%) had PD-L1 TPS scores ≥50%. Also 41 patients (33.3%) were treated with anti-PD-1 drugs (14 as first line, 19 as second and 8 as third). Eighteen of the patients who were treated with anti-PD-1 drugs were initially staged as IVA (43.9%) and 7 as IVB (17.1%). 14 out of 31 patients (20.4%) had disease control (8 SD and 6 PR/CR). Conclusions: In this retrospective analysis we found that the percentage of patients with PD-L1 expression ≥50% was 16% which is much lower than it was usually noticed in clinical trials. This could be probably attributed to the high percentage of patients with early or locally advanced tumors who were included. Legal entity responsible for the study: Pulmonary Department, Oncology Unit, Aristotle University of Thessaloniki. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
THU-271-Metabolic syndrome increases the risk of hepatic fibrosis in subjects with increased alcohol consumption: Results from a population-based cohort
Authors: llorenç caballeria, ELISA POSE, guillem pera, Isabel Graupera, carmen exposito, mónica sabater, José-María Moreno, Elsa Solà, José-Manuel Fernández-Real, pere toran, Pere Ginès
Journal: Journal of Hepatology (2019)
Comparison between clinician- and patient-reporting of baseline (BL) and post-BL symptomatic toxicities in cancer cooperative group clinical trials (NCCTG N0591 [Alliance]).
Authors: Thomas Michael Atkinson, Daniel V. Satele, Jeff A. Sloan, Diana Mehedint, Jacqueline M. Lafky, Ethan M. Basch, Amylou C. Dueck
Journal: Journal of Clinical Oncology (2015)

9520 Background: Reporting of clinician-based toxicity assessment via the Common Terminology Criteria for Adverse Events (CTCAE) commonly does not distinguish between symptoms already present at BL versus those that develop during a trial. Therefore, current estimation of toxicities may include symptoms that predate trial entry. We hypothesize that patient (pts) provide more complete BL symptom reports than clinicians, and that these BL symptoms can be “subtracted” from those reported during a trial at the pt level to better understand which toxicities actually developed during the trial. Methods: Data were pooled from Alliance trials where at BL and throughout the trial, (1) clinician-reported symptomatic toxicities were documented with the CTCAE and (2) analogous pt self-reported symptoms were documented via a questionnaire. McNemar’s test was used to compare between clinician- and pt-reporting of: 1) BL prevalence, 2) maximum post-BL, and 3) worsening (i.e., BL subtracted) scores. Results: Across 26 trials, 24 clinician- and analogous pt-reported symptoms were captured for 2608 pts (median age 60, 62% female, 93% Caucasian, 97% non-Hispanic). For 20/24 (83%) symptoms at BL, pts reported a significantly higher prevalence (grade or score ≥ 1) than did clinicians. Prevalence using maximum post-BL was significantly different between clinicians and pts for 21 (88%) symptoms with 16/21 (76%) having a higher prevalence by the pt report. When subtracting BL, a significant difference between clinicians and pts was observed in 16/24 (67%) symptoms, with a lesser number (9/16, 56%) having a higher incidence by pt report. Conclusions: Clinicians consistently under-reported prevalence of BL symptoms compared to pts. Change from pt-reported BL assessment appears to more closely match clinician-graded AEs. This method should be considered for future pt-based toxicity assessments in clinical trials as a more accurate appraisal of symptoms attributable to study treatments rather than to pre-existing etiologies.
FRI-242-Absence of hepatitis C infection despite high-risk sexual behavior in a cohort of men who have sex with men screened in the community: preliminary results of SEXCHECK study
Authors: Pietro Malosso, Lorenzo Badia, Viola Guardigni, Renato Pascale, Alessandro Di Felice, Gabriella Verucchi, Pierluigi Viale, Alessandro Mattioli
Journal: Journal of Hepatology (2019)
Tumor infiltrating lymphocytes in cutaneous melanoma: Association with tumor characteristics and prognosis.
Authors: Burcak Karaca, Zeki Gokhan Surmeli, Atike Pinar, Bulent Karabulut, Ulus Ali Sanli, Ruchan Uslu
Journal: Journal of Clinical Oncology (2015)

e20101 Background: The association between lymphocyte infiltration status and disease characteristics of melanoma and whether lymphocyte infiltration status is independently related to prognosis in non-metastatic cutaneous melanoma patients were evaluated. Methods: Medical records of non-metastatic cutaneous melanoma patients admitted to our clinic between 2000 and 2014 were retrospectively reviewed. All consecutive patients with available data regarding primary histopathological characteristics were included. Patients were grouped into “brisk infiltration” and “non-brisk or no infiltration” groups according to lymphocyte infiltration status of primary tumor. Disease characteristics and survival outcomes were compared among two groups. Results: Overall, 224 patients were included. Brisk infiltration was detected in 40 (17.9%) patients. Among brisk infiltration and non-brisk/no infiltration groups; median age (53 vs 52 years, p:0.536), gender distribution, and ratio of ulcerated lesions were similar. Brisk infiltration was associated with lower Breslow thickness (median 2.83mm vs 3.54, p:0.024), lower mitotic count (median 2 vs 7/mm2, p:0.015 ), less local lymph node positivity (13.5% vs 35.8%, p:0,009). In a median follow-up duration of 50 months, 13 out of 40 patients (32.5%) with brisk lymphocyte infiltration, and 96 out of 184 patients (52.2%) with non-brisk/no infiltration had disease recurrences. Median disease-free survival duration was superior in brisk infiltration group (68.2 vs 35.8 months, p:0.014); 2 and 5 year disease-free survival rates were 89.2% and 56% in brisk, whereas 61.3% and 42.6% in the other group, respectively. In multivariable analysis, when adjusted for tumor thickness ( ≤ 2 mm vs > 2 mm) and lymph node status (positive vs negative), lymphocyte infiltration (brisk vs other) was not significantly associated with disease-free survival (Hazard ratio: 1.63, 95% CI: 0.83 – 3.19, p:0.158). Conclusions: Our results suggest that presence of brisk lymphocyte infiltration of primary melanoma is associated with lower Breslow thickness, less lymph node metastasis and lower mitotic count.
Association of Stratification by Dual Enrollment Status With Financial Penalties in the Hospital Readmissions Reduction Program
Authors: Karen E. Joynt Maddox, Mat Reidhead, Andrew C. Qi, David R. Nerenz
Journal: JAMA Internal Medicine (2019)

Beginning in fiscal year 2019, Medicare's Hospital Readmissions Reduction Program (HRRP) stratifies hospitals into 5 peer groups based on the proportion of each hospital's patient population that is dually enrolled in Medicare and Medicaid. The effect of this policy change is largely unknown.To identify hospital and state characteristics associated with changes in HRRP-related performance and penalties after stratification.A cross-sectional analysis was performed of all 3049 hospitals participating in the HRRP in fiscal years 2018 and 2019, using publicly available data on hospital penalties, merged with information on hospital characteristics and state Medicaid eligibility cutoffs.The HRRP, under the 2018 traditional method and the 2019 stratification method.Performance on readmissions, as measured by the excess readmissions ratio, and penalties under the HRRP both in relative percentage change and in absolute dollars.The study sample included 3049 hospitals. The mean proportion of dually enrolled beneficiaries ranged from 9.5% in the lowest quintile to 44.7% in the highest quintile. At the hospital level, changes in penalties ranged from an increase of $225 000 to a decrease of more than $436 000 after stratification. In total, hospitals in the lowest quintile of dual enrollment saw an increase of $12 330 157 in penalties, while those in the highest quintile of dual enrollment saw a decrease of $22 445 644. Teaching hospitals (odds ratio [OR], 2.13; 95% CI, 1.76-2.57; P < .001) and large hospitals (OR, 1.51; 95% CI, 1.22-1.86; P < .001) had higher odds of receiving a reduced penalty. Not-for-profit hospitals (OR, 0.64; 95% CI, 0.52-0.80; P < .001) were less likely to have a penalty reduction than for-profit hospitals, and hospitals in the Midwest (OR, 0.44; 95% CI, 0.34-0.57; P < .001) and South (OR, 0.42; 95% CI, 0.30-0.57; P < .001) were less likely to do so than hospitals in the Northeast. Hospitals with patients from the most disadvantaged neighborhoods (OR, 2.62; 95% CI, 2.03-3.38; P < .001) and those with the highest proportion of beneficiaries with disabilities (OR, 3.12; 95% CI, 2.50-3.90; P < .001) were markedly more likely to see a reduction in penalties, as were hospitals in states with the highest Medicaid eligibility cutoffs (OR, 1.79; 95% CI, 1.50-2.14; P < .001).Stratification of the hospitals under the HRRP was associated with a significant shift in penalties for excess readmissions. Policymakers should monitor the association of this change with readmission rates as well as hospital financial performance as the policy is fully implemented.
SAT-007-Survival and risk factors of mortality after emergency transjugular intrahepatic portosystemic shunt for uncontrolled acute variceal bleeding caused by cirrhosis-related portal hypertension
Authors: Manon Allaire, Aurélie Walter, Isabelle Ollivier-Hourmand, Cléa Rouillon, Olivier Sutter, Olivier Seror, Roland Amathieu, Nathalie Ganne, Jean Charles Nault, Thong Dao
Journal: Journal of Hepatology (2019)
SAT-052-Right psoas muscle area: Prognostic factor in patients with cirrhosis Child Pugh class C included on the waiting list for liver transplantation
Authors: Speranta Iacob, Catalina Stanescu, Razvan Iacob, Roxana Vadan, Cristian Gheorghe, Ioana Lupescu, Liana Gheorghe
Journal: Journal of Hepatology (2019)
Unexpected Risk Profile of a Large Pediatric Population With Brugada Syndrome
Authors: Andrea Mazzanti, Paz Ovics, Ayelet Shauer, Stefano Mameli, Maira Marino, Raffaella Bloise, Nicola Monteforte, Cristina Raimondo, Alice Maltret, Carlo Napolitano, Vincenzo Bagnardi, Silvia G. Priori
Journal: Journal of the American College of Cardiology (2019)
TCTAP A-063 Endothelial Shear Stress and Vascular Remodeling in Bioresorbable Scaffold and Metallic Stent in the ABSORB II Trial
Authors: Erhan Tenekecioglu, Yuki Katagiri, Ryo Torii, Christos V. Bourantas, Frank Gijsen, Yoshinobu Onuma, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2019)
Identification of Candidates for Longer Lung Cancer Screening Intervals Following a Negative Low-Dose Computed Tomography Result
Authors: Hilary A Robbins, Christine D Berg, Li C Cheung, Anil K Chaturvedi, Hormuzd A Katki
Journal: JNCI Journal of the National Cancer Institute (2019)

Lengthening the annual low-dose computed tomography (CT) screening interval for individuals at lowest risk of lung cancer could reduce harms and improve efficiency. We analyzed 23 328 participants in the National Lung Screening Trial who had a negative CT screen (no ≥4-mm nodules) to develop an individualized model for lung cancer risk after a negative CT. The Lung Cancer Risk Assessment Tool + CT (LCRAT+CT) updates "prescreening risk" (calculated using traditional risk factors) with selected CT features. At the next annual screen following a negative CT, risk of cancer detection was reduced among the 70% of participants with neither CT-detected emphysema nor consolidation (median risk = 0.2%, interquartile range [IQR] = 0.1%-0.3%). However, risk increased for the 30% with CT emphysema (median risk = 0.5%, IQR = 0.3%-0.8%) and the 0.6% with consolidation (median = 1.6%, IQR = 1.0%-2.5%). As one example, a threshold of next-screen risk lower than 0.3% would lengthen the interval for 57.8% of screen-negatives, thus averting 49.8% of next-screen false-positives among screen-negatives but delaying diagnosis for 23.9% of cancers. Our results support that many, but not all, screen-negatives might reasonably lengthen their CT screening interval.
SAT-126-Minimal hepatic encephalopathy: Proper diagnosis for a better quality of life
Authors: Vlad Taru, Mina Ignat, Madalina Indre, Antonella Forgione, Oana Nicoara-Farcau, Petra Fischer, Horia Stefanescu, Zeno Sparchez, Marcel Tantau, Bogdan Procopet
Journal: Journal of Hepatology (2019)
SAT-264-Prediction of hepatocellular carcinoma development using liver stiffness after sustained virological responses by magnetic resonance elastography in patients with chronic hepatitis C
Authors: Nobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, Shun Kaneko, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Namiki Izumi
Journal: Journal of Hepatology (2019)
Shifting the Paradigm — Applying Universal Standards of Care to Ebola Virus Disease
Authors: William A. Fischer, Ian Crozier, Daniel G. Bausch, Jean-Jacques Muyembe, Sabue Mulangu, Janet V. Diaz, Richard Kojan, David A. Wohl, Shevin T. Jacob
Journal: New England Journal of Medicine (2019)

Shifting the Paradigm As the treatment paradigm for patients with Ebola virus disease shifts from isolation to aggressive supportive care and antiviral therapy, the global health community can work...